NEW YORK (GenomeWeb) – Luminex reported strong quarterly financial results on Monday, but said it is delaying until further notice the start of clinical trials for Verigene 2, an automated multiplex instrument that the firm is developing for infectious disease testing.

Luminex acquired Verigene 2 when it acquired Nanosphere in 2016. When it did, the firm halted development of Aries 2, its own higher plex instrument, in favor of developing the Verigene 2 product, also called Atlas.